-Eyexora, a biotech company pioneering innovative therapies for ophthalmic diseases through a hub-and-spoke model, announced the establishment of its co-headquarters in Singapore, marking a major milestone in the company’s global expansion and deepening its commitment to advancing eye health worldwide. Eyexora’s seed financing was led by ClavystBio, a global life sciences investor based in Singapore, and its initial programs have been in-licensed from the Singapore Eye Research Institute (SERI).

The new Singapore headquarters will serve as a gateway to Eyexora’s growing activities across the Asia-Pacific region, supporting clinical development, research collaborations, and regional partnerships. This expansion further strengthens Eyexora’s collaboration with the Singapore Eye Research Institute (SERI), a long-standing partner in ophthalmic innovation.

Eyexora’s Singapore operations will be instrumental in driving the company’s mission to develop transformative, accessible treatments for patients with vision-threatening diseases, while advancing scientific collaboration in one of the world’s most dynamic healthcare innovation hubs.

“Singapore has become a global center for ophthalmic research and innovation, and we are proud to deepen our presence here,” said Theresa Heah, M.D., M.B.A., Chief Executive Officer and Vice Chair of the Board, Eyexora. “This new co-headquarters positions Eyexora at the heart of Asia-Pacific’s biomedical ecosystem and strengthens our collaboration with SERI. Together, we are accelerating the development of breakthrough therapies that can improve vision and quality of life for patients around the world.”

“This milestone reflects our vision to build a truly global ophthalmic company,” said William J. Link, Ph.D, Chairman of the Board at Eyexora. “Singapore’s strong research infrastructure and commitment to innovation make it an ideal base for expanding Eyexora’s partnerships and advancing the next generation of eye care solutions.”

“Eyexora’s new co-headquarters are a testament to Singapore’s leadership in ophthalmology research and clinical delivery, and position as a global life sciences hub,” said Khoo Shih, Ph.D, CEO, ClavystBio. “At ClavystBio, we are excited to partner seasoned leaders like Theresa, William and their team to accelerate meaningful innovations and make global health impact.”

Last month Eyexora announced the launch of its second spoke company, Y.ora Vision, Inc., focused on developing next-generation ophthalmic medical devices for glaucoma. The company’s creation, complementing initial spoke company, Serenora Therapeutics, Inc., underscores Eyexora’s commitment to building a global ecosystem of specialized ventures that advance innovation across key therapeutic areas in ophthalmology.

Eyexora’s Singapore co-headquarters complements its U.S. base in New York, and will anchor the company’s Asia-Pacific operations, including clinical, scientific, and strategic functions, as it continues to grow its global footprint.